Karolinska Development AB represents a value-driven corporate philosophy focused on enabling the commercialization of innovative life science technologies. The company is dedicated to improving human health and actively supports the development of breakthrough therapies and medical innovations. Karolinska Development AB strives for long-term financial success while prioritizing ethical and sustainable practices. By identifying promising projects and providing strategic guidance, funding, and industry expertise, the company accelerates the growth of healthcare companies and fosters collaborations within the life science sector. Karolinska Development AB's commitment to driving scientific advancements and delivering shareholder value positions it as a leading player in the industry.

Karolinska Development AB, a renowned Swedish life science investment company, primarily operates in Sweden. With its headquarters situated in Stockholm, the company focuses on identifying and developing innovations within the healthcare sector. Karolinska Development AB plays a crucial role in supporting the commercialization and growth of early-stage life science companies originating from Sweden's prestigious Karolinska Institutet. With an extensive network of contacts and partnerships, Karolinska Development AB drives advancements in the field of biomedicine, primarily within Sweden's vibrant life science ecosystem.

Karolinska Development AB, a leading Nordic life science investment company, has achieved several significant milestones. The company has successfully supported the growth of numerous innovative healthcare companies and fostered collaborations with top academic institutions. Karolinska Development has enabled the development and commercialization of several breakthrough therapies and medical technologies, addressing critical unmet medical needs. Its extensive portfolio encompasses companies focusing on various therapeutic areas, including oncology, rare diseases, and regenerative medicine. With its strategic investments and valuable expertise, Karolinska Development continues to play a vital role in advancing the life sciences industry and improving patient outcomes.

Karolinska Development AB is a leading investment company in the field of life sciences. Established in 2003, the company focuses on identifying and developing innovative pharmaceutical products and medical technologies. As a subsidiary of Karolinska Institutet Holding AB, Karolinska Development collaborates with academia, top-notch experts, and industry stakeholders to bring promising research and commercialize breakthrough innovations. The company's portfolio includes a diverse range of investments in companies involved in drug development, medical devices, diagnostics, and digital health solutions. Karolinska Development aims to leverage its extensive network and knowledge to drive the growth and success of its portfolio companies in the global healthcare market.

The main competitors of Karolinska Development AB in the market include other biotechnology and pharmaceutical companies focusing on innovation and drug development. Some notable competitors include AstraZeneca, Novartis, Pfizer, GlaxoSmithKline, and Johnson & Johnson. These companies compete in the same industry, striving to bring new drugs and therapies to the market. Karolinska Development AB sets itself apart through its expertise in evaluating and identifying promising early-stage life science opportunities.

Karolinska Development AB is primarily active in the life sciences and healthcare industries.

Karolinska Development AB operates as a life sciences investment company. The company's business model focuses on identifying, developing, and commercializing innovative healthcare technologies originating from leading academic research institutions in the Nordic region. Karolinska Development AB aims to support the growth of these projects by providing expertise, funding, and strategic guidance. By actively participating in the development process, the company strives to maximize the potential value of its portfolio of companies. Through partnerships and collaborations, Karolinska Development AB aims to advance medical innovations that address significant unmet medical needs, ultimately benefiting both patients and investors.

Karolinska Development의 P/E 비율은 -12.21입니다.

Karolinska Development의 P/S 비율은 163.22입니다.

AlleAktien 품질 점수는 현재 Karolinska Development에 대해 계산할 수 없습니다.

예상되는 Karolinska Development 매출은 2.04 백만 SEK입니다.

예상되는 Karolinska Development 이익은 -27.26 백만 SEK입니다.

Karolinska Development AB specializes in the development of medications and medical technologies. The company's business model is based on building partnerships with promising startups and research institutions in the healthcare sector and supporting them in bringing their products and technologies to market. The company operates in four strategic business areas: company formation, technology development, product development, and management consulting. Karolinska Development AB aims to become a leading company in the healthcare industry and promote the development of medications and medical technologies.

Karolinska Development은(는) 연간 번의 배당을 통해 0 SEK의 배당금을 지급합니다.

Karolinska Development의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Karolinska Development의 ISIN은 SE0002190926입니다.

Karolinska Development의 WKN은 A0M84G입니다.

Karolinska Development의 티커는 KDEV.ST입니다.

지난 12개월 동안 Karolinska Development은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Karolinska Development은(는) 0 SEK의 배당금을 지급할 것으로 예상됩니다.

Karolinska Development의 현재 배당 수익률은 입니다.

Karolinska Development은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Karolinska Development은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 SEK의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Karolinska Development은 '건강' 섹터에 속합니다.

Karolinska Development의 마지막 배당금을 0 SEK만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Karolinska Development는 0 SEK를 배당금으로 지급했습니다.

Karolinska Development의 배당금은 SEK에 지급됩니다.